US20150272813A1 - Systems and methods for electrical stimulation of the gastrointestinal tract for treatment of post-operative ileus - Google Patents
Systems and methods for electrical stimulation of the gastrointestinal tract for treatment of post-operative ileus Download PDFInfo
- Publication number
- US20150272813A1 US20150272813A1 US14/672,541 US201514672541A US2015272813A1 US 20150272813 A1 US20150272813 A1 US 20150272813A1 US 201514672541 A US201514672541 A US 201514672541A US 2015272813 A1 US2015272813 A1 US 2015272813A1
- Authority
- US
- United States
- Prior art keywords
- stimulator
- stimulation
- medical instrument
- gastrointestinal tract
- distal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H9/00—Pneumatic or hydraulic massage
- A61H9/0007—Pulsating
-
- A61M1/008—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0507—Electrodes for the digestive system
- A61N1/0509—Stomach and intestinal electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0103—Constructive details inflatable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1042—Alimentary tract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/005—Parameter used as control input for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/08—Other bio-electrical signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/63—Motion, e.g. physical activity
Definitions
- Embodiments of the present disclosure relate generally to medical instruments. More particularly, embodiments of the disclosure relate to medical instruments for use in medical applications, such as, for example, stimulation of the gastrointestinal (GI) tract for treatment of postoperative ileus (POI). Embodiments of the disclosure also cover methods of using such instruments.
- GI gastrointestinal
- POI postoperative ileus
- Postoperative ileus is the transient impairment of intestinal motility occurring after a surgical procedure. This is clinically characterized by abdominal pain and distress, abdominal distention, delayed passage of gas and stool, lack of bowel sounds, and accumulation of gas and fluid in the bowel that may result in nausea, pain, and vomiting. POI is a major health care problem that adversely influences many aspects of postoperative patient care including overall prolonged recovery, increased morbidity, and extended hospitalization.
- POI pathophysiologic basis
- POI normally resolves within four days following an abdominal surgical procedure but may range from not being present and/or as little as two days following laparoscopic surgery to more than 9 days after major abdominal surgeries, including laparotomies.
- the length of hospitalization following surgery depends on several factors such as surgical procedure, postoperative pain, patient's co-morbidities, and the duration of POI.
- Goldstein et al. found, in an article evaluating the inpatient economic burden of POI associated with abdominal surgery, that a hospital stay coded POI is both substantially more costly ($18,877 vs. $9,460 per case) and of longer duration (11.5 days vs. 5.5 days per case).
- Goldstein J L Matuszewski K A, Delaney C P, Senagore A, Chiao E F, Shah M, Meyer K, Bramley T. Inpatient economic burdern of postoperative ileus associated with abdominal surgery in the United States. P&T 2007; 32(2):82-90.
- the supportive therapies listed above may be controlled only before the provided nutrition fluid, or agent enters the body.
- a healthcare practitioner may not, once the supportive therapy is ingested, be able to make adjustments based on, for example, patient reaction or effectiveness.
- many of these conventional solutions must be prescribed to all pre-operative patients who may or may not develop POI, without the ability to select and treat only those patients that actually suffer from POI. As such, there exists a need for improved medical instruments and procedures for treatment of POI.
- Embodiments of the present disclosure provide systems and methods for stimulation of the gastrointestinal tract for treatment of post-operative ileus.
- the medical instrument may include an elongate component having a proximal end and a distal end and may be configured for insertion in a natural orifice of a patient and to traverse the gastrointestinal tract of the patient.
- the medical instrument may also include a handle at the proximal end; and a stimulator at the distal end, wherein the stimulator is configured to stimulate the gastrointestinal tract to effect coordination of contractile peristaltic waves.
- the medical instrument may include one or more of the following features: wherein the stimulator provides at least one of electrical, mechanical, and enteric stimulation; wherein the stimulator is configured to be in a collapsed state for insertion into the gastrointestinal tract, and wherein the stimulator is configured to expand from the collapsed state to a deployed state to contact an interior surface of the gastrointestinal tract; wherein the distal end of the tubular component includes at least one port for at least one of delivering food, delivering pharmacologic agents, removing waste, and removing gas; including a control unit configured to produce patterns of stimulation to the stimulator based on at least one of real-time user input and pre-set stimulation patterns; including a sensor for sensing at least one parameter of motion, stress, strain, contact impedance, electrical signals, and chemical biomarkers; wherein the control unit is configured to adjust stimulation provided by the stimulator based on the at least one parameter sensed by the sensor; wherein the distal end is positioned based on the at least one parameter; wherein the stimulator is expanded by
- the method may include positioning a distal portion of a medical instrument, including a stimulator configured to stimulate tissue, at a target region within the gastrointestinal tract; and stimulating tissue of the target region, via the stimulator, to effect coordination of peristaltic waves.
- the method may also include producing patterns of stimulation based on at least one of real-time user input and pre-set stimulation patterns; deploying the stimulator to be in physical or electrical communication with tissue of the target region; wherein the stimulator is deployed by expanding the stimulator; wherein the stimulator is deployed by inflation; wherein the stimulator is deployed via a pull-wire or pulley system; wherein stimulating tissue includes at least one of electrical, mechanical, and enteric stimulation; sensing a location of a contraction and selecting the target region based on the location of the contraction; sensing a parameter within the patient's body and basing a pattern for stimulating the target region on the sensed parameter; repeating the pattern for stimulation until sustained coordinated peristaltic waves are sensed stimulating the target region by delivering electrical pulses; protecting the stimulator of the medical instrument via a sheath; and/or wherein the target region within a gastrointestinal tract is a region of the small intestine.
- FIG. 1 illustrates an exemplary embodiment of a tubular component of a medical instrument inserted into a patient's natural body orifice
- FIG. 2 illustrates an exemplary embodiment of the tubular component including a proximal end, a variable length of tubing, and a distal end;
- FIG. 3 illustrates an exemplary embodiment of a handle portion connected to the proximal end of the tubular component
- FIG. 4 illustrates an exemplary embodiment of the distal end of the tubular component, including a port, sensors, and a distal assembly;
- FIGS. 5A and 5B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations
- FIGS. 6A and 6B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations
- FIGS. 7A and 7B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations
- FIGS. 8A and 8B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations
- FIG. 9 illustrates an alternative embodiment of a control unit including a delivery port and a removal port.
- FIG. 10 is a block diagram of an exemplary method of using medical devices disclosed herein.
- Embodiments of the present disclosure relate to systems and methods for treatment of POI.
- the medical device described herein works by stimulation of the GI tract. More specifically, in exemplary embodiments, the myenteric plexus and/or submuscosal plexus may be stimulated in order to promote resolution of POI through re-coordination of contractile peristaltic waves. A segment of gastrointestinal tract of only less than two inches may need to be stimulated in order to initiate a cascade effect on additional gastric pacemaker cells.
- the stimulation could be axial in nature, circumferential, or a combination thereof. Further, sustained stimulation over multiple hours may result in propagation of the stimulation effect to the distal parts of the GI tract, including the colon, and proximal parts, including the stomach.
- devices and methods of the present disclosure can be used post-operatively on only those patients that are affected with POI, as opposed to being prescribed to all pre-operative patients. Further, this internal device for electrically stimulating the GI tract may be externally controlled, as opposed to medication that, once ingested, may no longer be adjusted by a medical professional. Further, devices and methods of the present disclosure provide direct or very close electrical stimulation to the target region of the GI tract, as opposed to surface electrical stimulation which has to traverse layers of soft tissue and may not be specific to a targeted region.
- the medical device of the present disclosure may include a control unit and a tubular component.
- the tubular component may be comprised of three main components: (1) a variable length of tubing; (2) a handle, at the component's proximal end, for externally manipulating the tubular structure into, inside of, and out of the patient; and (3) a distal assembly at the distal portion of the tubular component.
- FIG. 1 depicts the tubular component 100 according to an exemplary embodiment of the disclosure.
- Tubular component 100 may be configured for insertion into a patient's body through an anatomical opening. Accordingly, tubular component 100 may be shaped and sized for placement into a patient via a body orifice or an incision.
- tubular component 100 may be inserted and extracted from the patient through the mouth or through the nasal canal 4 , as depicted in FIG. 1 . Both approaches will enable the user to insert and extract the device through the GI tract including, but not limited to, the esophagus 6 , stomach 8 , and the small intestine 2 . Additionally, tubular component 100 may be configured for a transrectal approach. Tubular component 100 may include, at least, a proximal end 110 , a distal end 130 , and lumen 122 extending the length of tubular component 100 between proximal end 110 and distal end 130 . Tubular component 100 can have any suitable length sufficient to reach the treatment site within a patient.
- the length of the tubular component 100 may be sufficient so that the proximal end 110 is external to the patient's body and the distal end 130 is internal to the patient's body, e.g. within the small intestine 2 .
- FIG. 1 depicts the tubular component 100 extending through an anatomical opening (depicted as the nose in FIG. 1 ), through the esophagus 6 , stomach 8 , and into the small intestine 2 .
- the distal end 130 may be in contact with the proximal small intestine lumen 2 .
- the distal end 130 may be within the jejunum of the small intestine 2 .
- the tubular component 100 may be configured in a similar manner to a nasojejunal (NJ) tube and may be inserted through the nasal passage and into the jejunum.
- NJ nasojejunal
- FIG. 2 shows an exemplary embodiment of tubular component 100 .
- Tubular component 100 may include, at least, three main components: (1) a variable length of tubing 120 ; (2) a handle portion 112 for externally manipulating the tubular component into, inside of, and out of the patient as further depicted in FIG. 3 ; and (3) a distal assembly 132 at the distal portion 130 of the tubular component.
- the variable length of tubing 120 extends between the proximal end 110 and the distal end 130 .
- the length of tubing 120 may vary depending upon patient need.
- the length of the tubular component may be sufficient so that the proximal end 110 is external to the patient's body and the distal end 130 is internal to the patient's body.
- the distal end 130 extends through an anatomical opening (i.e. the patient's mouth or nose) and may be in contact with the interior wall of the small intestine.
- Tubing 120 may be attached to the handle portion 112 at the proximal end 110 and at distal end 130 may be attached to a variety of components and mechanisms including, but not limited to, distal assembly 132 that may provide stimulation in the GI tract, as depicted in FIGS. 5-8 , and components that may deliver food and/or medicine and remove gases as depicted in FIG. 4 .
- the tubing 120 may be comprised of a hollow cylindrical structure wherein a lumen 122 extends from proximal end 110 to distal end 130 .
- the tubing 120 may include components embedded within the lumen 122 , including, but not limited to, (i) a wire 124 , as depicted in FIG. 2 , to conduct the electricity from the proximal end 110 at the handle portion 112 to the distal end 130 ; and (ii) a retraction mechanism, as will be further described below, that may deploy and retract a stimulation mechanism.
- the diameter of tubing 120 may be selected based on the desired application, with the largest diameter of tubing 120 generally chosen to be smaller than the typical diameter of the desired body lumen where tubing 120 may be used.
- Tubing 120 to be employed in the esophagus for example, may be smaller than tubing to be employed in the colon.
- the diameter (or any other dimension) of tubing 120 may also depend on the insertion location of tubing 120 . That is, if tubing 120 is desired to be used in a patient's colon but is intended to be inserted into a patient via the patient's nose, the diameter of tubing 120 may be selected to be smaller than a nasal passage of the tubing, for example.
- tubing 120 may be a tubular structure.
- This structure may have a substantially circular cross-section or an elliptical, oval, polygonal, or irregular cross-section may be employed, as desired.
- a select portion of tubing 120 such as, e.g., a distal portion, may have a cross-sectional configuration or dimension different from another portion, e.g., a proximal portion, of tubing 120 .
- tubing 120 may be flexible along its entire length or adapted for flexure along portions of its length. Alternatively, the distal end of tubing 120 may be flexible while the remainder of tubing 120 may be semi-rigid or otherwise relatively less flexible.
- Tubing 120 may be made of any suitable biocompatible material such as a polymeric, metallic, or rubber material.
- Tubing 120 or a portion thereof, may be also made from a malleable material, such as stainless steel or aluminum, allowing a physician to change the shape of tubing 120 before or during a procedure.
- tubing 120 may be composed of an extrusion of wire braided polymer material to impart flexibility.
- Tubing 120 may also be coated using suitable low friction material, such as TEFLON®, polyetheretherketone (PEEK), polyimide, nylon, polyethylene, or other lubricious polymer coatings, to reduce surface friction with the surrounding body tissues. Additionally or alternatively, one or portions of the surfaces of tubing 120 may be coated or otherwise covered with a non-conductive material for preventing short-circuiting between tubing 120 and electrically conductive elements, such as the electrodes described in more detail below.
- suitable low friction material such as TEFLON®, polyetheretherketone (PEEK), polyimide, nylon, polyethylene, or other lubricious polymer coatings, to reduce surface friction with the surrounding body tissues.
- PEEK polyetheretherketone
- polyimide polyimide
- nylon polyethylene
- polyethylene polyethylene
- Handle portion 112 is disposed at the proximal end 110 of the tubular component 100 .
- Handle portion 112 may be any known, suitable handle.
- Handle portion 112 may be externally manipulated by the user to facilitate entry and removal of the other attached device components to be inserted into, stay in, and be removed from the patient.
- handle portion 112 may include an electricity port 114 that may be removably attached to an electrical source (not shown) and may allow delivery of electrical energy, signals, and/or light to distal end 130 . Electricity may travel through electricity port 114 and wire 124 , as depicted in FIG. 2 , to provide stimulation of tissue in contact with the distal end 130 .
- Wire 124 may be insulated and/or placed in the wall of the tubing to protect it from mechanical damage and/or digestive fluids.
- Handle portion 112 may additionally include a delivery and removal port 116 for allowing delivery of, for example, food, fluid and/or medication to the distal end 130 and/or the removal of waste and/or gas from distal end 130 .
- Electricity port 114 and delivery/removal port 116 may connect to a control unit 900 as depicted in FIG. 9 , as will be further described below.
- electricity port 114 and delivery/removal port 116 may be implemented using a single port. It should also be noted that that the functions performed by electricity port 114 and/or delivery/removal port 116 , as described herein, may be implemented using multiple ports.
- the operation of the device and, in particular, the mechanisms disposed at the distal end 130 may be operated wirelessly. In that embodiment, at least certain functions performance by electricity port 114 may not be necessary.
- the distal end 130 of the tubular component 100 may be comprised of one or more of a sensing mechanism, an exchange mechanism, a retraction mechanism, a positioning mechanism, a protective mechanism, and/or a stimulation mechanism, all described below. It should be noted that any of the functions performed by each of these mechanisms, as described herein, may be implemented by a single mechanism or a combination of mechanisms.
- the medical device may include a sensing mechanism.
- the sensing mechanism may be configured to sense multiple key parameters such as, but not, limited to, motion, stress, strain, contact impedance, electrical signals, and/or chemical biomarkers.
- the sensing mechanism may include a plurality of sensors 180 of FIG. 4 at multiple locations along the length and circumference of the medical device.
- the programmed system and/or a control unit may be configured to utilize the data regarding these or other parameters to actively control or optimize the stimulation parameters and/or patterns. For example, the data from the sensing mechanism may be sent to the control unit to more optimally control the tissue stimulation in order to influence the contractions and/or relaxations in the intestinal smooth muscle cells.
- the sensing mechanism may also be used to help position the medical device, including the distal end 130 of the tubular component 100 .
- the sensing mechanism may sense at multiple locations along the length and circumference of the tubular component, contractions in the small intestine via impedance, stress, and/or strain or other modalities. The location of contractions may be used to ensure contact with a desired target region.
- the distal end 130 may include indicia, visible under various imaging regimes. For example, radiopaque or sonoreflective markings (not shown) may be added to an exterior surface of the distal end 130 or distal assembly 132 to indicate position and orientation during a procedure. That information can enable the user to track the medical device, ensure contact with the target region, and avoid potential damage to sensitive tissues.
- the distal end 130 may also include a protective mechanism that may be configured to protect the stimulation mechanism and/or other components (e.g. pharmacologic agents) from mechanical damage and/or digestive fluids.
- the protective mechanism may serve to prevent scratching along the nasal-jejunal passage and/or prevent digestive enzymes from inactivating the pharmacologic agent(s) that may exist on the device for delivery at the treatment site.
- the protective mechanism may include, but is not limited to, an insulated tube or a sheath-like mechanism that can be placed in the wall of tube 120 or within lumen 122 of tube 120 .
- the protective mechanism may assist in re-capturing and re-positioning the stimulation mechanism.
- a sheath from the protective mechanism or a separate sheath may be used to steer and position the tubular component 100 .
- This positioning sheath may be on the exterior of the distal end 130 of the tubular component 100 and adapted to be moved into a body lumen.
- the positioning sheath may be fitted with steering capability, actuated by control wires or rods. Steering devices are well known in the art and will not be described further here.
- the distal end 130 of the tubular component 100 may also, or alternatively, include a retraction mechanism to deploy and retract stimulators of the medical device, at the targeted region within the GI tract.
- the retraction mechanism may include a pulley to deploy and retract the stimulation mechanism.
- a pull wire may have one end attached to the distal assembly (e.g. stimulation mechanism) and another end attached to the handle. Extension and retraction of the pull wire will deploy and contract the distal assembly, respectively.
- the retraction mechanism may, as will be further described below, also include inflating a balloon or sliding a sheath.
- the distal end 130 of the tubular component 100 may also, or alternatively, include an exchange mechanism at the distal end 130 .
- FIG. 4 illustrates an alternative embodiment of distal end 130 of the tubular component 100 that may be connected to distal assembly 132 for providing stimulation and may include distal port 118 .
- Distal port 118 may be capable of delivering food and/or fluids to, or removing gases from the targeted region of the GI tract.
- Distal port 118 may deliver pharmalogical medication to enterically stimulate the GI tract, alone or in combination with other stimulation modalities.
- Delivery/removal port 116 of handle 112 as depicted in FIG. 3 , may be fluidly connected to distal port 118 .
- Distal port 118 of FIG. 4 is exemplary and the exchange mechanism of the present disclosure may utilize multiple ports or other passages for the delivery and/or removal.
- the distal end 130 may include a stimulation mechanism.
- the stimulation mechanism may, alone or in combination, have the ability to mechanically, electrically, or enterically stimulate (via, e.g., pharmacologic agent or other suitable modality) the GI tract. These stimulation modalities may operate alone, or incorporated with other stimulation modalities.
- the stimulation may be delivered through distal assembly 132 as depicted in FIG. 4 .
- the parameters for stimulation may be, for example, random, set by the user, or based on the parameter sensed by the sensing mechanism (e.g. motion, stress, strain, contact impedance, electrical signals, and/or chemical biomarkers). These parameters may be induced in unique patterns to optimize the GI response.
- the stimulation may also be configured to (or as a mere accidental side effect) interfere with pain in the GI reflexes that may be contributing to POI.
- the stimulation mechanism may be through controlled mechanical manipulation.
- the stimulation mechanism may produce mechanical forces within the lumen of the small intestine to further promote controlled contractile activity. Mechanical manipulation may invoke the stretch receptors in the GI tract, specifically the jejunum, to induce coordinated peristaltic waves.
- the stimulation mechanism may stimulate the GI tract electrically.
- electrical stimulation may “reset” the electrical pacing system of the entire GI tract, or just a portion that is causing lack of coordinated bowel activity.
- a distal assembly 132 at the distal end 130 may include an arrangement of one or more flexible electrodes.
- the electrodes may, for example, be individually placed on the length of insulated wire (e.g., the Constellation Catheter by Boston Scientific Corporation of Maple Grove, Minn.), may span the entire uninsulated portion of the wire, or may be integrated into a flexible mesh or conductive material in order to maximize contact with the interior wall 22 of the small intestine 2 .
- the electrodes may all be stimulating electrodes or some may be grounding electrodes and some stimulating electrodes.
- the electrodes may all stimulate simultaneously or in a pre-determined fashion such as to promote a cascade effect on the next cluster of adjacent gastric pacemaker cells, e.g. inches away.
- the distance between electrodes may be between 0-5′′ apart.
- the distal assembly 132 connected to the distal end 130 of the tubular component 100 may be comprised of electrical stimulators, such as electrodes, arranged in numerous configurations. Exemplary configurations are depicted in FIGS. 5-8 .
- the electrical stimulators may be in a collapsed state upon insertion into the patient and then be deployed upon reaching the targeted area within the GI tract.
- the electrical stimulators may be designed to physically touch or be in electrical communication with an interior surface of the target region of the GI tract and may provide stimulation through physical contact or an electric field.
- the distal assembly 132 In an expanded/deployed state, the distal assembly 132 may be configured to anchor the medical device within the body.
- the electrical stimulators may be configured to deliver electrical impulses capable of stimulating soft tissue, such as nerves and muscle, in the target region of the GI tract in order to generate contractions.
- FIGS. 5A and 5B depict an alternative configuration of distal assembly 132 of FIGS. 2 and 4 , wherein assembly 532 has a balloon-like′ configuration.
- FIG. 5A depicts assembly 532 (connected to distal end 130 of tubing 120 ) in the collapsed state after insertion into small intestine 2 .
- the mechanisms of deployment and/or retraction of the electrical stimulators on assembly 532 may be via an inflatable system to expand assembly 532 .
- FIG. 5B depicts 532 in its deployed state, in which assembly 532 is inflated until the electrical stimulators are in physical contact or electric communication with the interior wall 22 of the small intestine 2 at least at points 534 .
- FIG. 6A illustrates assembly 632 , connected to distal end 130 and after insertion into the small intestine 2 .
- assembly 632 is in its collapsed state.
- the mechanisms of deployment and/or retraction of the electrical stimulators on assembly 632 may be via a pull-wire or pulley system, wherein the distal end of assembly 632 is configured to be pulled toward proximal end 110 .
- a pull-wire 635 may be attached to a distal ring 636 and to the handle at the proximal end. Pulling pull-wire 635 retracts 636 to expand/deploy assembly 632 .
- FIG. 6B depicts assembly 632 in its deployed state, in which the electrical stimulators of assembly 632 are in physical contact or electric communication with the interior wall 22 of the small intestine 2 at least at points 634 .
- FIG. 7A depicts the collapsed state and FIG. 7B depicts the deployed state of an alternative embodiment of distal end 130 in which assembly 732 has a ‘flower petal’ configuration.
- the petals 736 of FIGS. 7A and 7B have rounded ends.
- the deployment mechanism may be a pull-wire or pulley mechanism whereupon the user pulls an attached wire that can deploy or retract the electrical stimulators.
- the deployment mechanism may additionally or alternatively employ a sheath to hold petals 736 of assembly 732 in a collapsed position until assembly 732 is pushed distally or the sheath is pulled proximally, thus allowing petals 736 of assembly 734 to transition to their natural, expanded state.
- the petals 736 may be configured to expand until the electrical stimulators of petals 736 are in physical contact and/or electrical communication with interior surface 22 of small intestine 2 at least at points 734 .
- FIGS. 8A and 8B depict a ‘brush-like’ electrical stimulator configuration whereupon when the electrical stimulators are deployed they bend outwardly, like bristles of a paintbrush.
- the deployment mechanism may be, but is not limited to, a pull-wire or pulley mechanism whereupon the user pulls an attached wire that can deploy or retract the electrical stimulators. Additionally or alternatively, a deployment sheath may cover and then uncover the stimulators to allow them to expand to a biased position.
- FIG. 8A illustrates assembly 832 in the collapsed state.
- FIG. 8B illustrates assembly 832 in the deployed state, wherein the electrical stimulators may contact interior wall 22 of small intestine 2 at least at points 834 .
- distal assemblies are merely exemplary and distal assembly 132 and the electrodes thereon may be configured in any arrangement. Even though the assemblies in the examples above contact the interior walls of the small intestine, the stimulation mechanism may be configured to stimulate any portion of the GI tract.
- stimulation through a pharmacologic agent may be utilized alone or incorporated into the electrical and/or mechanical stimulation mechanisms.
- stimulation through a pharmacologic agent may include an enteric coating around the mechanical and/or electrical stimulators.
- pharmacologic agents may be released through distal port 118 located at the distal end of the tubular component 100 , as depicted in FIG. 4 .
- the disclosed medical device may also include a control unit, as depicted in FIG. 9 , capable of interfacing with handle portion 112 of the tubular component 100 to provide electricity to the electrical stimulators, to deliver food through the food port 116 a , or expel gas through the gas port 116 b from the targeted region of the GI tract depending upon desired usage of the device by the user.
- the control unit 900 may be powered by an external source such as an electrical outlet.
- the control unit 900 may include buttons, knobs, touchscreens, or other user interfaces to control the sensing mechanism.
- the control unit 900 may be housed in the handle itself or in a separate apparatus.
- the control unit 900 may be configured to enable the user to set patterns of electrical stimulation or may have pre-set electrical stimulation patterns.
- the voltage may range 0.5 to 1.5V.
- an electrical stimulation pattern may include a repeating stimulation pattern of 1V, 4 mA for 5 seconds, then 55 seconds off until resolution of POI.
- the data from the sensing mechanism may be integrated to optimally control the stimulations to influence the contractions and/or relaxations in the intestinal smooth muscle cells.
- the pattern of electrical stimulation may be sequenced proximal to distal or vice versa.
- the electrical stimulation may be staggered or with the stimulators and grounds at varying locations on the electrodes. For example, the distal end of the stimulator would stimulate first and then, e.g., 0.5 seconds (or any suitable predetermined time) later the proximal end of the stimulator would stimulate. Additionally or alternatively, like with the Constellation Catheter, the electrodes located most distally and proximally may be the stimulators and then the middle electrodes would serve as the grounds. Control 910 may be configured to turn the device on and off, or may be used to set or select patterns, including those referenced above.
- FIG. 10 illustrates an exemplary method of use of a medical device for treatment of POI.
- the tubular component of the medical device may be inserted into the nose or mouth of a patient's body.
- the tubular component may be further inserted through the esophagus, stomach, and into the small intestine until it reaches the target region.
- the target region may be, for example, the duodenum or the jejunal region of the small intestine.
- the user may deploy electrically stimulating components, such as electrodes, to be in electrical communication with the target region of the GI tract (step 1030 ).
- the stimulators may be electrical, mechanical, or enteric, or a combination thereof.
- the electrical stimulator may deliver electrical impulses to the target region.
- the stimulation may be complete after, for example, a predetermined amount of time, once the user determines, or once a parameter is observed that indicates the stimulation is a success (such as a motion within the GI tract that indicates sustained coordinated contractions have commenced).
- Stimulation may not be complete as defined by step 1050 , until several rounds of electrical stimulation have been applied. For example, one round of electrical stimulation lasting approximately 5 hours may be applied to the target region.
- the device would remain within the GI tract at the target region while a healthcare practitioner or the control unit interpret the parameters sensed by the sensing mechanism.
- the device may be removed.
- additional rounds of electrical impulses may be applied at the target region.
- the user may additionally choose to move the device into a more distal region of the GI tract, and apply additional electrical impulses at the new target region. This could be repeated and the device may remain in the patient, cycling through a program for, e.g., 16-24 hours or more before moving to step 1060 .
- the electrical stimulator may be retracted into a collapsed position, in step 1060 . After retraction of the electrical stimulator, the tubular component may be removed from the patient's body.
- the user may retract the electrical stimulator, reposition, redeploy, and begin to deliver electrical impulses to a new target region. The steps may be repeated until the stimulation is determined complete (i.e. once sustained coordinated contractions of the GI tract begin).
- the target region may be selected based on the location of contractions in the GI tract. This location may be determined based on parameters sensed by the sensing mechanism, as described above.
- the electrical impulses of step 1040 may be delivered in a pattern.
- This pattern may be pre-set, determined in real-time by the user, or these impulses may be actively controlled and optimized based on parameters collected from the sensing mechanism and implemented by the control unit, as described above. These parameters may include motion, stress, strain, contact impedance, electrical signals, and/or chemical biomarkers.
Abstract
The present disclosure is directed to a medical instrument. Systems and methods are provided for stimulation of the gastrointestinal tract. The medical instrument may include an elongate component having a proximal end and a distal end. The medical instrument may be configured for insertion in a natural orifice of a patient and to traverse the gastrointestinal tract of the patient. The medical instrument may include a handle at the proximal end and a stimulator at the distal end wherein the stimulator may be configured to stimulate the gastrointestinal tract to effect coordination of peristaltic waves.
Description
- This application claims the benefit of priority from U.S. Provisional Application No. 61/973,005, filed on Mar. 31, 2014, which is incorporated by reference herein in its entirety.
- Embodiments of the present disclosure relate generally to medical instruments. More particularly, embodiments of the disclosure relate to medical instruments for use in medical applications, such as, for example, stimulation of the gastrointestinal (GI) tract for treatment of postoperative ileus (POI). Embodiments of the disclosure also cover methods of using such instruments.
- Postoperative ileus (POI) is the transient impairment of intestinal motility occurring after a surgical procedure. This is clinically characterized by abdominal pain and distress, abdominal distention, delayed passage of gas and stool, lack of bowel sounds, and accumulation of gas and fluid in the bowel that may result in nausea, pain, and vomiting. POI is a major health care problem that adversely influences many aspects of postoperative patient care including overall prolonged recovery, increased morbidity, and extended hospitalization.
- The exact pathophysiologic basis of POI is unknown, although it is believed to be multifactorial and includes three major mechanisms; neurogenic, inflammatory, and pharmacologic. POI normally resolves within four days following an abdominal surgical procedure but may range from not being present and/or as little as two days following laparoscopic surgery to more than 9 days after major abdominal surgeries, including laparotomies. The length of hospitalization following surgery depends on several factors such as surgical procedure, postoperative pain, patient's co-morbidities, and the duration of POI.
- POI increases the utilization of hospital resources because discharge after surgery is typically delayed until the patient can tolerate a regular diet and acceptably healthy bowel function is restored. Data from the Health Care Financing Administration (HCFA) showed that in 2000, a total of 161,000 Medicare patients underwent major abdominal colorectal procedures, stayed in the hospital 1.82 million days (a mean of 11.3 days per patient), and cost approximately $1.75 billion.
- Goldstein et al. found, in an article evaluating the inpatient economic burden of POI associated with abdominal surgery, that a hospital stay coded POI is both substantially more costly ($18,877 vs. $9,460 per case) and of longer duration (11.5 days vs. 5.5 days per case). (Goldstein J L, Matuszewski K A, Delaney C P, Senagore A, Chiao E F, Shah M, Meyer K, Bramley T. Inpatient economic burdern of postoperative ileus associated with abdominal surgery in the United States. P&T 2007; 32(2):82-90.) This study documented that the total annual United States hospital cost attributed to managing cases coded POI is $1.46 billion for both the index hospitalization and any readmissions within 30 days.
- Current management strategies consist of careful selection of anesthesia and analgesia before, during, and after surgery to minimize the duration of POI and the use of supportive therapies such as enteral nutrition, intravenous fluids and pharmacological agents (i.e., laxatives and prokinetic drugs). However, these strategies are not uniformly successful and patients are often slow to respond to them.
- For example, the supportive therapies listed above, including pharmacological agents, may be controlled only before the provided nutrition fluid, or agent enters the body. In some cases, a healthcare practitioner may not, once the supportive therapy is ingested, be able to make adjustments based on, for example, patient reaction or effectiveness. Further, many of these conventional solutions must be prescribed to all pre-operative patients who may or may not develop POI, without the ability to select and treat only those patients that actually suffer from POI. As such, there exists a need for improved medical instruments and procedures for treatment of POI.
- Embodiments of the present disclosure provide systems and methods for stimulation of the gastrointestinal tract for treatment of post-operative ileus.
- One embodiment of the present disclosure is directed to a medical instrument. The medical instrument may include an elongate component having a proximal end and a distal end and may be configured for insertion in a natural orifice of a patient and to traverse the gastrointestinal tract of the patient. The medical instrument may also include a handle at the proximal end; and a stimulator at the distal end, wherein the stimulator is configured to stimulate the gastrointestinal tract to effect coordination of contractile peristaltic waves.
- In various embodiments, the medical instrument may include one or more of the following features: wherein the stimulator provides at least one of electrical, mechanical, and enteric stimulation; wherein the stimulator is configured to be in a collapsed state for insertion into the gastrointestinal tract, and wherein the stimulator is configured to expand from the collapsed state to a deployed state to contact an interior surface of the gastrointestinal tract; wherein the distal end of the tubular component includes at least one port for at least one of delivering food, delivering pharmacologic agents, removing waste, and removing gas; including a control unit configured to produce patterns of stimulation to the stimulator based on at least one of real-time user input and pre-set stimulation patterns; including a sensor for sensing at least one parameter of motion, stress, strain, contact impedance, electrical signals, and chemical biomarkers; wherein the control unit is configured to adjust stimulation provided by the stimulator based on the at least one parameter sensed by the sensor; wherein the distal end is positioned based on the at least one parameter; wherein the stimulator is expanded by inflation; wherein the stimulator is expanded via a pull-wire or pulley system; wherein the interior surface of the gastrointestinal tract is a portion of the small intestine of the patient; including a protective sheath; wherein the stimulator is configured to stimulate the gastrointestinal tract in a pattern of repeating stimulation; wherein the pattern comprises a stimulation of between 0.5V and 1.5V; and/or repeating the pattern for stimulation until sustained coordinated peristaltic waves are sensed.
- Another embodiment of the present disclosure is directed to a method for treatment of a gastrointestinal tract. The method may include positioning a distal portion of a medical instrument, including a stimulator configured to stimulate tissue, at a target region within the gastrointestinal tract; and stimulating tissue of the target region, via the stimulator, to effect coordination of peristaltic waves. The method may also include producing patterns of stimulation based on at least one of real-time user input and pre-set stimulation patterns; deploying the stimulator to be in physical or electrical communication with tissue of the target region; wherein the stimulator is deployed by expanding the stimulator; wherein the stimulator is deployed by inflation; wherein the stimulator is deployed via a pull-wire or pulley system; wherein stimulating tissue includes at least one of electrical, mechanical, and enteric stimulation; sensing a location of a contraction and selecting the target region based on the location of the contraction; sensing a parameter within the patient's body and basing a pattern for stimulating the target region on the sensed parameter; repeating the pattern for stimulation until sustained coordinated peristaltic waves are sensed stimulating the target region by delivering electrical pulses; protecting the stimulator of the medical instrument via a sheath; and/or wherein the target region within a gastrointestinal tract is a region of the small intestine.
- Additional objects and advantages of the disclosed embodiments will be set forth in part in the description that follows, and in part will be apparent from the description, or may be learned by practice of the disclosed embodiments. The objects and advantages of the disclosed embodiments will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
- It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the scope of disclosed embodiments, as set forth by the claims.
- The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate various exemplary embodiments and together with the description, serve to explain the principles of the disclosed embodiments.
-
FIG. 1 illustrates an exemplary embodiment of a tubular component of a medical instrument inserted into a patient's natural body orifice; -
FIG. 2 illustrates an exemplary embodiment of the tubular component including a proximal end, a variable length of tubing, and a distal end; -
FIG. 3 illustrates an exemplary embodiment of a handle portion connected to the proximal end of the tubular component; -
FIG. 4 illustrates an exemplary embodiment of the distal end of the tubular component, including a port, sensors, and a distal assembly; -
FIGS. 5A and 5B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations; -
FIGS. 6A and 6B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations; -
FIGS. 7A and 7B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations; -
FIGS. 8A and 8B illustrate a distal portion of the tubular component including an alternative embodiment of the distal assembly in its collapsed and deployed configurations; -
FIG. 9 illustrates an alternative embodiment of a control unit including a delivery port and a removal port; and -
FIG. 10 is a block diagram of an exemplary method of using medical devices disclosed herein. - Reference will now be made in detail to exemplary embodiments of the disclosure, examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.
- Embodiments of the present disclosure relate to systems and methods for treatment of POI. The medical device described herein works by stimulation of the GI tract. More specifically, in exemplary embodiments, the myenteric plexus and/or submuscosal plexus may be stimulated in order to promote resolution of POI through re-coordination of contractile peristaltic waves. A segment of gastrointestinal tract of only less than two inches may need to be stimulated in order to initiate a cascade effect on additional gastric pacemaker cells. The stimulation could be axial in nature, circumferential, or a combination thereof. Further, sustained stimulation over multiple hours may result in propagation of the stimulation effect to the distal parts of the GI tract, including the colon, and proximal parts, including the stomach.
- Unlike a pill or other pharmacological agents used for conventional solutions, devices and methods of the present disclosure can be used post-operatively on only those patients that are affected with POI, as opposed to being prescribed to all pre-operative patients. Further, this internal device for electrically stimulating the GI tract may be externally controlled, as opposed to medication that, once ingested, may no longer be adjusted by a medical professional. Further, devices and methods of the present disclosure provide direct or very close electrical stimulation to the target region of the GI tract, as opposed to surface electrical stimulation which has to traverse layers of soft tissue and may not be specific to a targeted region.
- A. The Tubular Component
- The medical device of the present disclosure may include a control unit and a tubular component. The tubular component may be comprised of three main components: (1) a variable length of tubing; (2) a handle, at the component's proximal end, for externally manipulating the tubular structure into, inside of, and out of the patient; and (3) a distal assembly at the distal portion of the tubular component.
-
FIG. 1 depicts thetubular component 100 according to an exemplary embodiment of the disclosure.Tubular component 100 may be configured for insertion into a patient's body through an anatomical opening. Accordingly,tubular component 100 may be shaped and sized for placement into a patient via a body orifice or an incision. - In some embodiments,
tubular component 100 may be inserted and extracted from the patient through the mouth or through the nasal canal 4, as depicted inFIG. 1 . Both approaches will enable the user to insert and extract the device through the GI tract including, but not limited to, theesophagus 6,stomach 8, and thesmall intestine 2. Additionally,tubular component 100 may be configured for a transrectal approach.Tubular component 100 may include, at least, aproximal end 110, adistal end 130, andlumen 122 extending the length oftubular component 100 betweenproximal end 110 anddistal end 130.Tubular component 100 can have any suitable length sufficient to reach the treatment site within a patient. The length of thetubular component 100 may be sufficient so that theproximal end 110 is external to the patient's body and thedistal end 130 is internal to the patient's body, e.g. within thesmall intestine 2.FIG. 1 depicts thetubular component 100 extending through an anatomical opening (depicted as the nose inFIG. 1 ), through theesophagus 6,stomach 8, and into thesmall intestine 2. In some embodiments, thedistal end 130 may be in contact with the proximalsmall intestine lumen 2. In other embodiments, thedistal end 130 may be within the jejunum of thesmall intestine 2. For example, thetubular component 100 may be configured in a similar manner to a nasojejunal (NJ) tube and may be inserted through the nasal passage and into the jejunum. -
FIG. 2 shows an exemplary embodiment oftubular component 100.Tubular component 100 may include, at least, three main components: (1) a variable length oftubing 120; (2) ahandle portion 112 for externally manipulating the tubular component into, inside of, and out of the patient as further depicted inFIG. 3 ; and (3) adistal assembly 132 at thedistal portion 130 of the tubular component. - 1. The Tubing
- The variable length of
tubing 120 extends between theproximal end 110 and thedistal end 130. The length oftubing 120 may vary depending upon patient need. The length of the tubular component may be sufficient so that theproximal end 110 is external to the patient's body and thedistal end 130 is internal to the patient's body. In certain embodiments, thedistal end 130 extends through an anatomical opening (i.e. the patient's mouth or nose) and may be in contact with the interior wall of the small intestine. -
Tubing 120 may be attached to thehandle portion 112 at theproximal end 110 and atdistal end 130 may be attached to a variety of components and mechanisms including, but not limited to,distal assembly 132 that may provide stimulation in the GI tract, as depicted inFIGS. 5-8 , and components that may deliver food and/or medicine and remove gases as depicted inFIG. 4 . - In some embodiments, the
tubing 120 may be comprised of a hollow cylindrical structure wherein alumen 122 extends fromproximal end 110 todistal end 130. Thetubing 120 may include components embedded within thelumen 122, including, but not limited to, (i) awire 124, as depicted inFIG. 2 , to conduct the electricity from theproximal end 110 at thehandle portion 112 to thedistal end 130; and (ii) a retraction mechanism, as will be further described below, that may deploy and retract a stimulation mechanism. - The diameter of
tubing 120 may be selected based on the desired application, with the largest diameter oftubing 120 generally chosen to be smaller than the typical diameter of the desired body lumen wheretubing 120 may be used.Tubing 120 to be employed in the esophagus, for example, may be smaller than tubing to be employed in the colon. Those of ordinary skill will recognize that the diameter (or any other dimension) oftubing 120 may also depend on the insertion location oftubing 120. That is, iftubing 120 is desired to be used in a patient's colon but is intended to be inserted into a patient via the patient's nose, the diameter oftubing 120 may be selected to be smaller than a nasal passage of the tubing, for example. In one embodiment,tubing 120 may be a tubular structure. This structure may have a substantially circular cross-section or an elliptical, oval, polygonal, or irregular cross-section may be employed, as desired. In addition, a select portion oftubing 120, such as, e.g., a distal portion, may have a cross-sectional configuration or dimension different from another portion, e.g., a proximal portion, oftubing 120. Moreover,tubing 120 may be flexible along its entire length or adapted for flexure along portions of its length. Alternatively, the distal end oftubing 120 may be flexible while the remainder oftubing 120 may be semi-rigid or otherwise relatively less flexible. Flexibility allowstubing 120 to maneuver turns in body lumens, while some level of rigidity provides a structure upon which the operator can exert the necessary force to urgetubing 120 forward.Tubing 120 may be made of any suitable biocompatible material such as a polymeric, metallic, or rubber material.Tubing 120, or a portion thereof, may be also made from a malleable material, such as stainless steel or aluminum, allowing a physician to change the shape oftubing 120 before or during a procedure. In some instances,tubing 120 may be composed of an extrusion of wire braided polymer material to impart flexibility.Tubing 120 may also be coated using suitable low friction material, such as TEFLON®, polyetheretherketone (PEEK), polyimide, nylon, polyethylene, or other lubricious polymer coatings, to reduce surface friction with the surrounding body tissues. Additionally or alternatively, one or portions of the surfaces oftubing 120 may be coated or otherwise covered with a non-conductive material for preventing short-circuiting betweentubing 120 and electrically conductive elements, such as the electrodes described in more detail below. - 2. The Handle Portion
-
Handle portion 112 is disposed at theproximal end 110 of thetubular component 100.Handle portion 112 may be any known, suitable handle.Handle portion 112 may be externally manipulated by the user to facilitate entry and removal of the other attached device components to be inserted into, stay in, and be removed from the patient. As illustrated inFIG. 3 , handleportion 112 may include anelectricity port 114 that may be removably attached to an electrical source (not shown) and may allow delivery of electrical energy, signals, and/or light todistal end 130. Electricity may travel throughelectricity port 114 andwire 124, as depicted inFIG. 2 , to provide stimulation of tissue in contact with thedistal end 130.Wire 124 may be insulated and/or placed in the wall of the tubing to protect it from mechanical damage and/or digestive fluids.Handle portion 112 may additionally include a delivery andremoval port 116 for allowing delivery of, for example, food, fluid and/or medication to thedistal end 130 and/or the removal of waste and/or gas fromdistal end 130.Electricity port 114 and delivery/removal port 116 may connect to acontrol unit 900 as depicted inFIG. 9 , as will be further described below. - It should be noted that the functions performed by
electricity port 114 and delivery/removal port 116, as described herein, may be implemented using a single port. It should also be noted that that the functions performed byelectricity port 114 and/or delivery/removal port 116, as described herein, may be implemented using multiple ports. - Further, in an alternative embodiment, the operation of the device and, in particular, the mechanisms disposed at the
distal end 130 may be operated wirelessly. In that embodiment, at least certain functions performance byelectricity port 114 may not be necessary. - 3. The Distal End
- The
distal end 130 of thetubular component 100 may be comprised of one or more of a sensing mechanism, an exchange mechanism, a retraction mechanism, a positioning mechanism, a protective mechanism, and/or a stimulation mechanism, all described below. It should be noted that any of the functions performed by each of these mechanisms, as described herein, may be implemented by a single mechanism or a combination of mechanisms. - The medical device may include a sensing mechanism. The sensing mechanism may be configured to sense multiple key parameters such as, but not, limited to, motion, stress, strain, contact impedance, electrical signals, and/or chemical biomarkers. The sensing mechanism may include a plurality of
sensors 180 ofFIG. 4 at multiple locations along the length and circumference of the medical device. The programmed system and/or a control unit may be configured to utilize the data regarding these or other parameters to actively control or optimize the stimulation parameters and/or patterns. For example, the data from the sensing mechanism may be sent to the control unit to more optimally control the tissue stimulation in order to influence the contractions and/or relaxations in the intestinal smooth muscle cells. - The sensing mechanism may also be used to help position the medical device, including the
distal end 130 of thetubular component 100. The sensing mechanism may sense at multiple locations along the length and circumference of the tubular component, contractions in the small intestine via impedance, stress, and/or strain or other modalities. The location of contractions may be used to ensure contact with a desired target region. In another embodiment, thedistal end 130 may include indicia, visible under various imaging regimes. For example, radiopaque or sonoreflective markings (not shown) may be added to an exterior surface of thedistal end 130 ordistal assembly 132 to indicate position and orientation during a procedure. That information can enable the user to track the medical device, ensure contact with the target region, and avoid potential damage to sensitive tissues. - In one embodiment, the
distal end 130 may also include a protective mechanism that may be configured to protect the stimulation mechanism and/or other components (e.g. pharmacologic agents) from mechanical damage and/or digestive fluids. For example, the protective mechanism may serve to prevent scratching along the nasal-jejunal passage and/or prevent digestive enzymes from inactivating the pharmacologic agent(s) that may exist on the device for delivery at the treatment site. The protective mechanism may include, but is not limited to, an insulated tube or a sheath-like mechanism that can be placed in the wall oftube 120 or withinlumen 122 oftube 120. In some embodiments, the protective mechanism may assist in re-capturing and re-positioning the stimulation mechanism. - A sheath from the protective mechanism or a separate sheath may be used to steer and position the
tubular component 100. This positioning sheath may be on the exterior of thedistal end 130 of thetubular component 100 and adapted to be moved into a body lumen. As known in the art, the positioning sheath may be fitted with steering capability, actuated by control wires or rods. Steering devices are well known in the art and will not be described further here. - The
distal end 130 of thetubular component 100 may also, or alternatively, include a retraction mechanism to deploy and retract stimulators of the medical device, at the targeted region within the GI tract. The retraction mechanism may include a pulley to deploy and retract the stimulation mechanism. For example, a pull wire may have one end attached to the distal assembly (e.g. stimulation mechanism) and another end attached to the handle. Extension and retraction of the pull wire will deploy and contract the distal assembly, respectively. The retraction mechanism may, as will be further described below, also include inflating a balloon or sliding a sheath. - The
distal end 130 of thetubular component 100 may also, or alternatively, include an exchange mechanism at thedistal end 130.FIG. 4 illustrates an alternative embodiment ofdistal end 130 of thetubular component 100 that may be connected todistal assembly 132 for providing stimulation and may includedistal port 118.Distal port 118 may be capable of delivering food and/or fluids to, or removing gases from the targeted region of the GI tract.Distal port 118 may deliver pharmalogical medication to enterically stimulate the GI tract, alone or in combination with other stimulation modalities. Delivery/removal port 116 ofhandle 112, as depicted inFIG. 3 , may be fluidly connected todistal port 118.Distal port 118 ofFIG. 4 is exemplary and the exchange mechanism of the present disclosure may utilize multiple ports or other passages for the delivery and/or removal. - The
distal end 130 may include a stimulation mechanism. The stimulation mechanism may, alone or in combination, have the ability to mechanically, electrically, or enterically stimulate (via, e.g., pharmacologic agent or other suitable modality) the GI tract. These stimulation modalities may operate alone, or incorporated with other stimulation modalities. The stimulation may be delivered throughdistal assembly 132 as depicted inFIG. 4 . - In some embodiments, the parameters for stimulation may be, for example, random, set by the user, or based on the parameter sensed by the sensing mechanism (e.g. motion, stress, strain, contact impedance, electrical signals, and/or chemical biomarkers). These parameters may be induced in unique patterns to optimize the GI response. The stimulation may also be configured to (or as a mere accidental side effect) interfere with pain in the GI reflexes that may be contributing to POI.
- In one embodiment, the stimulation mechanism may be through controlled mechanical manipulation. The stimulation mechanism may produce mechanical forces within the lumen of the small intestine to further promote controlled contractile activity. Mechanical manipulation may invoke the stretch receptors in the GI tract, specifically the jejunum, to induce coordinated peristaltic waves.
- In some embodiments, the stimulation mechanism may stimulate the GI tract electrically. For example, electrical stimulation may “reset” the electrical pacing system of the entire GI tract, or just a portion that is causing lack of coordinated bowel activity. In such embodiments, a
distal assembly 132 at thedistal end 130 may include an arrangement of one or more flexible electrodes. The electrodes may, for example, be individually placed on the length of insulated wire (e.g., the Constellation Catheter by Boston Scientific Corporation of Maple Grove, Minn.), may span the entire uninsulated portion of the wire, or may be integrated into a flexible mesh or conductive material in order to maximize contact with theinterior wall 22 of thesmall intestine 2. The electrodes may all be stimulating electrodes or some may be grounding electrodes and some stimulating electrodes. The electrodes may all stimulate simultaneously or in a pre-determined fashion such as to promote a cascade effect on the next cluster of adjacent gastric pacemaker cells, e.g. inches away. The distance between electrodes may be between 0-5″ apart. - The
distal assembly 132 connected to thedistal end 130 of thetubular component 100 may be comprised of electrical stimulators, such as electrodes, arranged in numerous configurations. Exemplary configurations are depicted inFIGS. 5-8 . The electrical stimulators may be in a collapsed state upon insertion into the patient and then be deployed upon reaching the targeted area within the GI tract. The electrical stimulators may be designed to physically touch or be in electrical communication with an interior surface of the target region of the GI tract and may provide stimulation through physical contact or an electric field. In an expanded/deployed state, thedistal assembly 132 may be configured to anchor the medical device within the body. The electrical stimulators may be configured to deliver electrical impulses capable of stimulating soft tissue, such as nerves and muscle, in the target region of the GI tract in order to generate contractions. -
FIGS. 5A and 5B depict an alternative configuration ofdistal assembly 132 ofFIGS. 2 and 4 , whereinassembly 532 has a balloon-like′ configuration.FIG. 5A depicts assembly 532 (connected todistal end 130 of tubing 120) in the collapsed state after insertion intosmall intestine 2. The mechanisms of deployment and/or retraction of the electrical stimulators onassembly 532 may be via an inflatable system to expandassembly 532.FIG. 5B depicts 532 in its deployed state, in whichassembly 532 is inflated until the electrical stimulators are in physical contact or electric communication with theinterior wall 22 of thesmall intestine 2 at least at points 534. -
FIG. 6A illustratesassembly 632, connected todistal end 130 and after insertion into thesmall intestine 2. InFIG. 6A ,assembly 632 is in its collapsed state. The mechanisms of deployment and/or retraction of the electrical stimulators onassembly 632 may be via a pull-wire or pulley system, wherein the distal end ofassembly 632 is configured to be pulled towardproximal end 110. For example, a pull-wire 635 may be attached to adistal ring 636 and to the handle at the proximal end. Pulling pull-wire 635 retracts 636 to expand/deployassembly 632.FIG. 6B depicts assembly 632 in its deployed state, in which the electrical stimulators ofassembly 632 are in physical contact or electric communication with theinterior wall 22 of thesmall intestine 2 at least at points 634. -
FIG. 7A depicts the collapsed state andFIG. 7B depicts the deployed state of an alternative embodiment ofdistal end 130 in whichassembly 732 has a ‘flower petal’ configuration. Thepetals 736 ofFIGS. 7A and 7B have rounded ends. The deployment mechanism may be a pull-wire or pulley mechanism whereupon the user pulls an attached wire that can deploy or retract the electrical stimulators. The deployment mechanism may additionally or alternatively employ a sheath to holdpetals 736 ofassembly 732 in a collapsed position untilassembly 732 is pushed distally or the sheath is pulled proximally, thus allowingpetals 736 ofassembly 734 to transition to their natural, expanded state. Thepetals 736 may be configured to expand until the electrical stimulators ofpetals 736 are in physical contact and/or electrical communication withinterior surface 22 ofsmall intestine 2 at least at points 734. -
FIGS. 8A and 8B depict a ‘brush-like’ electrical stimulator configuration whereupon when the electrical stimulators are deployed they bend outwardly, like bristles of a paintbrush. The deployment mechanism may be, but is not limited to, a pull-wire or pulley mechanism whereupon the user pulls an attached wire that can deploy or retract the electrical stimulators. Additionally or alternatively, a deployment sheath may cover and then uncover the stimulators to allow them to expand to a biased position.FIG. 8A illustrates assembly 832 in the collapsed state.FIG. 8B illustrates assembly 832 in the deployed state, wherein the electrical stimulators may contactinterior wall 22 ofsmall intestine 2 at least at points 834. - The disclosed distal assemblies are merely exemplary and
distal assembly 132 and the electrodes thereon may be configured in any arrangement. Even though the assemblies in the examples above contact the interior walls of the small intestine, the stimulation mechanism may be configured to stimulate any portion of the GI tract. - In another embodiment, stimulation through a pharmacologic agent may be utilized alone or incorporated into the electrical and/or mechanical stimulation mechanisms. In one embodiment, stimulation through a pharmacologic agent may include an enteric coating around the mechanical and/or electrical stimulators. In another embodiment, pharmacologic agents may be released through
distal port 118 located at the distal end of thetubular component 100, as depicted inFIG. 4 . - B. Control unit
- The disclosed medical device may also include a control unit, as depicted in
FIG. 9 , capable of interfacing withhandle portion 112 of thetubular component 100 to provide electricity to the electrical stimulators, to deliver food through the food port 116 a, or expel gas through the gas port 116 b from the targeted region of the GI tract depending upon desired usage of the device by the user. Thecontrol unit 900 may be powered by an external source such as an electrical outlet. In addition to those features shown, thecontrol unit 900 may include buttons, knobs, touchscreens, or other user interfaces to control the sensing mechanism. Thecontrol unit 900 may be housed in the handle itself or in a separate apparatus. - The
control unit 900 may be configured to enable the user to set patterns of electrical stimulation or may have pre-set electrical stimulation patterns. For example, the voltage may range 0.5 to 1.5V. In one embodiment, an electrical stimulation pattern may include a repeating stimulation pattern of 1V, 4 mA for 5 seconds, then 55 seconds off until resolution of POI. - In another example, the data from the sensing mechanism may be integrated to optimally control the stimulations to influence the contractions and/or relaxations in the intestinal smooth muscle cells. In an additional example, the pattern of electrical stimulation may be sequenced proximal to distal or vice versa. The electrical stimulation may be staggered or with the stimulators and grounds at varying locations on the electrodes. For example, the distal end of the stimulator would stimulate first and then, e.g., 0.5 seconds (or any suitable predetermined time) later the proximal end of the stimulator would stimulate. Additionally or alternatively, like with the Constellation Catheter, the electrodes located most distally and proximally may be the stimulators and then the middle electrodes would serve as the grounds.
Control 910 may be configured to turn the device on and off, or may be used to set or select patterns, including those referenced above. - C. Methods for Operation
-
FIG. 10 illustrates an exemplary method of use of a medical device for treatment of POI. As shown instep 1010, at least a portion of the tubular component of the medical device may be inserted into the nose or mouth of a patient's body. Instep 1020, the tubular component may be further inserted through the esophagus, stomach, and into the small intestine until it reaches the target region. The target region may be, for example, the duodenum or the jejunal region of the small intestine. Once the device is at the target region, the user may deploy electrically stimulating components, such as electrodes, to be in electrical communication with the target region of the GI tract (step 1030). In some embodiments, the stimulators may be electrical, mechanical, or enteric, or a combination thereof. Instep 1040, the electrical stimulator may deliver electrical impulses to the target region. The stimulation may be complete after, for example, a predetermined amount of time, once the user determines, or once a parameter is observed that indicates the stimulation is a success (such as a motion within the GI tract that indicates sustained coordinated contractions have commenced). Stimulation may not be complete as defined bystep 1050, until several rounds of electrical stimulation have been applied. For example, one round of electrical stimulation lasting approximately 5 hours may be applied to the target region. The device would remain within the GI tract at the target region while a healthcare practitioner or the control unit interpret the parameters sensed by the sensing mechanism. If sustained coordinated contractions are sensed during the break from electrical stimulation, the device may be removed. Alternatively, if sustained coordinated contractions are not sensed or are not within desired parameters, additional rounds of electrical impulses may be applied at the target region. The user may additionally choose to move the device into a more distal region of the GI tract, and apply additional electrical impulses at the new target region. This could be repeated and the device may remain in the patient, cycling through a program for, e.g., 16-24 hours or more before moving to step 1060. Once the stimulation is complete (as determined in step 1050), the electrical stimulator may be retracted into a collapsed position, instep 1060. After retraction of the electrical stimulator, the tubular component may be removed from the patient's body. - In some embodiments, if the user determines that the stimulation is unsuccessful, before
step 1050, the user may retract the electrical stimulator, reposition, redeploy, and begin to deliver electrical impulses to a new target region. The steps may be repeated until the stimulation is determined complete (i.e. once sustained coordinated contractions of the GI tract begin). - In some embodiments, the target region may be selected based on the location of contractions in the GI tract. This location may be determined based on parameters sensed by the sensing mechanism, as described above.
- In certain embodiments, the electrical impulses of
step 1040 may be delivered in a pattern. This pattern may be pre-set, determined in real-time by the user, or these impulses may be actively controlled and optimized based on parameters collected from the sensing mechanism and implemented by the control unit, as described above. These parameters may include motion, stress, strain, contact impedance, electrical signals, and/or chemical biomarkers. - The many features and advantages of the disclosure are apparent from the detailed specification, and thus, it is intended by the appended claims to cover all such features and advantages of the disclosure which fall within the true spirit and scope of the disclosure. Further, since numerous modifications and variations will readily occur to those skilled in the art, it is not desired to limit the disclosure to the exact construction and operation illustrated and described, and accordingly, all suitable modifications and equivalents may be resorted to, falling within the scope of the disclosure.
- Other embodiments of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims (20)
1. A medical instrument, comprising:
an elongate component having a proximal end and a distal end, wherein the medical instrument is configured for insertion in a natural orifice of a patient and to traverse the gastrointestinal tract of the patient;
a handle at the proximal end; and
a stimulator at the distal end, wherein the stimulator is configured to stimulate the gastrointestinal tract to effect coordination of contractile peristaltic waves.
2. The medical instrument of claim 1 , wherein the stimulator provides at least one of electrical, mechanical, and enteric stimulation.
3. The medical instrument of claim 1 , wherein the stimulator is configured to be in a collapsed state for insertion into the gastrointestinal tract, and wherein the stimulator is configured to expand from the collapsed state to a deployed state to contact an interior surface of the gastrointestinal tract.
4. The medical instrument of claim 1 , wherein the distal end of the elongate component includes at least one port for at least one of delivering food, delivering pharmacologic agents, removing waste, and removing gas.
5. The medical instrument of claim 1 , further comprising a control unit configured to control one or more stimulation patterns of the stimulator based on at least one of real-time user input and pre-set stimulation patterns.
6. The medical instrument of claim 5 , further comprising a sensor for sensing at least one parameter of motion, stress, strain, contact impedance, electrical signals, and chemical biomarkers, wherein the control unit is configured to adjust stimulation provided by the stimulator based on the least one parameter sensed by the sensor.
7. The medical instrument of claim 6 , wherein the distal end is positioned based on the at least one parameter.
8. The medical instrument of claim 1 , wherein the stimulator is configured to stimulate the gastrointestinal tract in a pattern of repeating stimulation, wherein the pattern comprises a stimulation of between 0.5V and 1.5V, until sustained coordinated peristaltic waves are sensed.
9. A medical instrument, comprising:
an elongate component having a proximal end and a distal end, wherein the medical instrument is configured for insertion in a natural orifice of a patient and to traverse the gastrointestinal tract of the patient;
a handle at the proximal end; and
a stimulator at the distal end, wherein the stimulator is configured to stimulate the gastrointestinal tract to effect coordination of contractile peristaltic waves.
10. The medical instrument of claim 9 , wherein the stimulator provides at least one of electrical, mechanical, and enteric stimulation.
11. The medical instrument of claim 9 , wherein the stimulator is configured to be in a collapsed state for insertion into the gastrointestinal tract, and wherein the stimulator is configured to expand from the collapsed state to a deployed state to contact an interior surface of the gastrointestinal tract.
12. The medical instrument of claim 9 , wherein the distal end of the elongate component includes at least one port for at least one of delivering food, delivering pharmacologic agents, removing waste, and removing gas.
13. The medical instrument of claim 9 , further comprising a control unit configured to control one or more stimulation patterns of the stimulator based on at least one of real-time user input and pre-set stimulation patterns.
14. The medical instrument of claim 13 , further comprising a sensor for sensing at least one parameter of motion, stress, strain, contact impedance, electrical signals, and chemical biomarkers, wherein the control unit is configured to adjust stimulation provided by the stimulator based on the least one parameter sensed by the sensor.
15. A method for treatment of a gastrointestinal tract, comprising:
positioning a distal portion of a medical instrument, including a stimulator configured to stimulate tissue, at a target region within the gastrointestinal tract; and
stimulating tissue of the target region, via the stimulator, to effect coordination of peristaltic waves.
16. The method of claim 15 , further comprising producing patterns of stimulation based on at least one of real-time user input and pre-set stimulation patterns.
17. The method of claim 15 , further comprising deploying the stimulator to be in physical or electrical communication with tissue of the target region.
18. The method of claim 15 , wherein stimulating tissue includes at least one of electrical, mechanical, and enteric stimulation.
19. The method of claim 15 , further comprising sensing a location of a contraction and selecting the target region based on the location of the contraction.
20. The method of claim 19 , further comprising sensing a parameter within the patient's body and basing a pattern for stimulating the target region on the sensed parameter, and repeating the pattern for stimulation until sustained coordinated peristaltic waves are sensed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/672,541 US20150272813A1 (en) | 2014-03-31 | 2015-03-30 | Systems and methods for electrical stimulation of the gastrointestinal tract for treatment of post-operative ileus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461973005P | 2014-03-31 | 2014-03-31 | |
US14/672,541 US20150272813A1 (en) | 2014-03-31 | 2015-03-30 | Systems and methods for electrical stimulation of the gastrointestinal tract for treatment of post-operative ileus |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150272813A1 true US20150272813A1 (en) | 2015-10-01 |
Family
ID=52829437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/672,541 Abandoned US20150272813A1 (en) | 2014-03-31 | 2015-03-30 | Systems and methods for electrical stimulation of the gastrointestinal tract for treatment of post-operative ileus |
Country Status (4)
Country | Link |
---|---|
US (1) | US20150272813A1 (en) |
EP (1) | EP3125992A1 (en) |
CN (1) | CN106413804A (en) |
WO (1) | WO2015153427A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111134924A (en) * | 2020-01-20 | 2020-05-12 | 中国人民解放军第四军医大学 | Emetic device for emergency department nursing |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109589488B (en) * | 2019-01-11 | 2021-07-30 | 陈锋 | Intestinal obstruction dredging device |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080058887A1 (en) * | 2006-04-25 | 2008-03-06 | Bobby Griffin | Methods and devices for gastrointestinal stimulation |
US20080249507A1 (en) * | 2004-12-01 | 2008-10-09 | Vision - Sciences Inc. | Emergency Electrode on Medical Tube |
US20090187098A1 (en) * | 2004-04-21 | 2009-07-23 | Acclarent, Inc. | Devices, Systems and Methods for Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose, and/or Throat |
US20100030256A1 (en) * | 1997-11-12 | 2010-02-04 | Genesis Technologies Llc | Medical Devices and Methods |
WO2014022436A1 (en) * | 2012-07-30 | 2014-02-06 | Fractyl Laboratories Inc. | Electrical energy ablation systems, devices and methods for the treatment of tissue |
US20150343211A1 (en) * | 2012-12-24 | 2015-12-03 | E-Motion Medical, Ltd. | Gi tract stimulation devices and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3411507A (en) * | 1964-04-01 | 1968-11-19 | Medtronic Inc | Method of gastrointestinal stimulation with electrical pulses |
EP1261294B1 (en) * | 2000-03-10 | 2006-11-29 | Paracor Medical, Inc. | Expandable cardiac harness for treating congestive heart failure |
US7702394B2 (en) * | 2001-05-01 | 2010-04-20 | Intrapace, Inc. | Responsive gastric stimulator |
US7167750B2 (en) * | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
KR20130111206A (en) * | 2010-05-02 | 2013-10-10 | 레이크 바이오사이언스, 엘엘씨 | Modulating function of the facial nerve system or related neural structures via the ear |
WO2012109297A2 (en) * | 2011-02-10 | 2012-08-16 | Atrial Innovations, Inc. | Atrial appendage occlusion and arrhythmia treatment |
CN203436670U (en) * | 2013-09-13 | 2014-02-19 | 王照飞 | Gastric content backflow resistant and slippage-preventing type gastric tube having pressure regulating function |
-
2015
- 2015-03-30 US US14/672,541 patent/US20150272813A1/en not_active Abandoned
- 2015-03-30 WO PCT/US2015/023286 patent/WO2015153427A1/en active Application Filing
- 2015-03-30 CN CN201580026881.7A patent/CN106413804A/en active Pending
- 2015-03-30 EP EP15716326.2A patent/EP3125992A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100030256A1 (en) * | 1997-11-12 | 2010-02-04 | Genesis Technologies Llc | Medical Devices and Methods |
US20090187098A1 (en) * | 2004-04-21 | 2009-07-23 | Acclarent, Inc. | Devices, Systems and Methods for Diagnosing and Treating Sinusitis and Other Disorders of the Ears, Nose, and/or Throat |
US20080249507A1 (en) * | 2004-12-01 | 2008-10-09 | Vision - Sciences Inc. | Emergency Electrode on Medical Tube |
US20080058887A1 (en) * | 2006-04-25 | 2008-03-06 | Bobby Griffin | Methods and devices for gastrointestinal stimulation |
WO2014022436A1 (en) * | 2012-07-30 | 2014-02-06 | Fractyl Laboratories Inc. | Electrical energy ablation systems, devices and methods for the treatment of tissue |
US20150343211A1 (en) * | 2012-12-24 | 2015-12-03 | E-Motion Medical, Ltd. | Gi tract stimulation devices and methods |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111134924A (en) * | 2020-01-20 | 2020-05-12 | 中国人民解放军第四军医大学 | Emetic device for emergency department nursing |
Also Published As
Publication number | Publication date |
---|---|
WO2015153427A1 (en) | 2015-10-08 |
EP3125992A1 (en) | 2017-02-08 |
CN106413804A (en) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8032222B2 (en) | Device for electrically and mechanically stimulating a compartment in a body | |
AU2007281071B2 (en) | Methods and devices for stimulation of an organ with the use of a transectionally placed guide wire | |
US9919152B2 (en) | Conditional gastrointestinal stimulation for improved motility | |
EP2723445B1 (en) | Esophageal stimulation devices | |
BR112015002311B1 (en) | Electrical ablation device and method of treating tissue electrosurgically | |
ES2867076T3 (en) | Endoluminal nerve modulation device | |
CN107126622A (en) | neural stimulation system | |
EP3060152B1 (en) | Catheter apparatuses for modulation of nerves in communication with the pulmonary system and associated systems | |
JP6615977B2 (en) | Smart device for bladder mapping | |
US20150272813A1 (en) | Systems and methods for electrical stimulation of the gastrointestinal tract for treatment of post-operative ileus | |
US8868215B2 (en) | Apparatus and methods for minimally invasive obesity treatment | |
AU2007202075B2 (en) | Medical instrument having a catheter and method for using a catheter | |
US20210322769A1 (en) | Apparatus and method for transoral minimally invasive treatment of gastrointestinal diseases | |
US20230026849A1 (en) | Transesophageal vagus nerve stimulation | |
JP2021522976A (en) | Medical device including instrument grip | |
WO2021067111A2 (en) | Apparatus and method for deploying medical device for gastrointestinal diseases | |
Welch | Design of Medical Devices for Diagnostics in the Gastrointestinal System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: REGENTS OF THE UNIVERSITY OF MINNESOTA, MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RIZQ, RAED;REEL/FRAME:037770/0134 Effective date: 20150325 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |